Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?

Seminars in Dialysis

Volumn 18, Issue 1, 2005, Pages 22-29

  Berns, Jeffrey S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; COST BENEFIT ANALYSIS; DIALYSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG SCREENING; DRUG USE; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH PROGRAM; HEART DISEASE; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; MEDICAL INFORMATION; METHODOLOGY; MORTALITY; PATIENT; PATIENT CARE; POPULATION; PRACTICE GUIDELINE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; QUALITY OF LIFE; REIMBURSEMENT; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SUBSTITUTION THERAPY; SURVIVAL; UNITED STATES;

ANEMIA; CLINICAL TRIALS; ERYTHROPOIETIN, RECOMBINANT; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; PRACTICE GUIDELINES; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 14844314917     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2005.18105.x     Document Type: Review

References (68)

1. Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN: Appendix A. In: Wintrobe MM (ed.). Wintrobe's Clinical Hematology, 9th ed. Philadelphia: Lea & Febiger, 1993:2303
2. World Health Organization: Nutritional Anaemias: Report of a WHO Scientific Group. Geneva, Switzerland: World Health Organization, 1968
3. Kazmi WH, Kausz AT, Khan S, Abichandani R, Ruthazer R, Obrador GT, Pereira BJ: Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis 38:803-812, 2001
4. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O: Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 34:125-134, 1999
5. Jurkovitz CT, Abramson JL, Vaccarino LV, Weintraub WS, McClellan WM: Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based Atherosclerosis Risk in Communities (ARIC) study. J Am Soc Nephrol 14:2919-2925, 2003
6. Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W: Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC study. Kidney Int 64:610-615, 2003
7. Sarnak MJ, Tighiouart H, Manjunath G, MacLeod B, Griffith J, Salem D, Levey AS: Anemia as a risk factor for cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 40:27-33, 2002
8. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R: Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 13:1928-1936, 2002
9. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O: Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77:176-185, 1997
10. Ma JZ, Ebben J, Xia H, Collins AJ: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10:610-619, 1999
11. Xia H, Ebben J, Ma JZ, Collins AJ: Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 10:1309-1316, 1999
12. Collins AJ, Li S, St Peter W, Ebben J, Roberts T, Ma JZ, Manning W: Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36-39%. J Am Soc Nephrol 12:2465-2473, 2001
13. Obrador GT, Roberts T, St Peter WL, Frazier E, Pereira BJ, Collins AJ: Trends in anemia at initiation of dialysis in the United States. Kidney Int 60:1875-1884, 2001
14. USRDS: the United States Renal Data System. Am J Kidney Dis 42(6 suppl 5):1-230, 2003
15. Eschbach JW, Varma A, Stivelman JC: Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia? Nephrol Dial Transplant 17(suppl 5):2-7, 2002
16. Fink J, Blahut S, Reddy M, Light P: Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 37:348-355, 2001
17. Xue JL, St Peter WL, Ebben JP, Everson SE, Collins AJ: Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis 40:1153-1161, 2002
18. National Kidney Foundation: NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 30(suppl 3):S192-S240, 1997
19. National Kidney Foundation: NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 37(suppl 1):S182-S238, 2001
20. Barren BJ, Fenton SS, Ferguson B, Halligan P, Langlois S, McCready WG, Muirhead N, Weir RV: Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. Canadian Society of Nephrology. J Am Soc Nephrol 10(suppl 13):S292-S296, 1999
21. Working Party for European Best Practices Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure: Target Guideline 5: target haemoglobin concentration for the treatment of the anaemia of chronic renal failure. Nephrol Dial Transplant 14:11-13, 1999
22. SECTION II. Targets for anaemia treatment. Nephrol Dial Transplant 19(suppl 2):ii6-ii15, 2004
23. Jones M, Ibels L, Schenkel B, Zagari M: Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int 65:757-767, 2004
24. Stevens L, Stigant C, Levin A: Should hemoglobin be normalized in patients with chronic kidney disease? Semin Dial 15:8-13, 2002
25. Jacobs C: Normalization of haemoglobin: why not? Nephrol Dial Transplant 14(suppl 2):75-79, 1999
26. Besarab A, Aslam M: Should the hematocrit (hemoglobin) be normalized in pre-ESRD or dialysis patients? Yes! Blood Purif 19:168-174, 2001
27. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al.: Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111:992-1000, 1989
28. Collins AJ, Ma JZ, Xia A, Ebben J: Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 32:S133-S141, 1998
29. Madore F, Lowrie EG, Brugnara C, Lew NL, Lazarus JM, Bridges K, Owen WF: Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol 8:1921-1929, 1997
30. Li S, Collins AJ: Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int 65:626-633, 2004
31. Avram MM, Blaustein D, Fein PA, Goel N, Chattopadhyay J, Mittman N: Hemoglobin predicts long-term survival in dialysis patients: a 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin. Kidney Int Suppl 87:S6-S11, 2003
32. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM: The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 63:1908-1914, 2003
33. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590, 1998
34. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ: Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 15:1425-1430, 2000
35. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. The US Recombinant Human Erythropoietin Predialysis Study Group. Am J Kidney Dis 18:50-59, 1991
36. Pickett JL, Theberge DC, Brown WS, Schweitzer SU, Nissenson AR: Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 33:1122-1130, 1999
37. McMahon LP, McKenna MJ, Sangkabutra T, Mason K, Sostaric S, Skinner SL, Burge C, Murphy B, Crankshaw D: Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. Nephrol Dial Transplant 14:1182-1187, 1999
38. Painter P, Moore G, Carlson L, Paul S, Myll J, Phillips W, Haskell W: Effects of exercise training plus normalization of hematocrit on exercise capacity and health-related quality of life. Am J Kidney Dis 39:257-265, 2002
39. Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G, Schwartz D, Baruch R, Yachnin T, Shaked M, Schwartz I, Steinbruch S, Iaina A: The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 18:141-146, 2003
40. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 27:347-354, 1996
41. Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A: Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 29:541-548, 1997
42. Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, Imai E, Hori M: Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 35:250-256, 2000
43. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58:1325-1335, 2000
44. Roger SD, McMahon LP, Clarkson A, Disney A, Harris D, Hawley C, Healy H, Kerr P, Lynn K, Parnham A, Pascoe R, Voss D, Walker R, Levin A: Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 15:148-156, 2004
45. McMahon LP, Roger SD, Levin A: Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease. J Am Soc Nephrol 15:1640-1647, 2004
46. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F: Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 11:335-342, 2000
47. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG: A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 18:353-361, 2003
48. Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, Greenwood R, Feldman HI, Port FK, Held PJ: Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19:121-132, 2004
49. Kelleher BP, Wall C, O'Brian SD: Haemoglobin, not hematocrit, should be the preferred parameter for the evaluation of anaemia in renal patients [letter]. Nephrol Dial Transplant 16:1085-1087, 2001
50. Appendix A: haematology methodology. Nephrol Dial Transplant 19(suppl 2):ii37-ii38, 2004
51. Bellizzi V, Minutolo R, Terracciano V, Iodice C, Giannattasio P, De Nicola L, Conte G, Di Iorio BR: Influence of the cyclic variation of hydration status on hemoglobin levels in hemodialysis patients. Am J Kidney Dis 40:549-555, 2002
52. Cheung AK, Yan G, Greene T, Daugirdas JT, Dwyer JT, Levin NW, Ornt DB, Schulman G, Eknoyan G, Hemodialysis Study Group: Seasonal variations in clinical and laboratory variables among chronic hemodialysis patients. J Am Soc Nephrol 13:2345-2352, 2002
53. Lacson E Jr, Ofsthun N, Lazarus JM: Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 41:111-124, 2003
54. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB: Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 64:1514-1521, 2003
55. Wish JB: Can evidence drive the development of a sound national EPO reimbursement policy? Am J Kidney Dis 41:254-258, 2003
56. Freund LE, Nielsen SM: Statistical process control concepts for managing erythropoietin therapy [abstract]. J Am Soc Nephrol 11:A1401, 2000
57. Brier ME, Aronoff GR: Hemoglobin goals and the natural variability in the erythropoietin response [abstract]. J Am Soc Nephrol 13:628A, 2002
58. Raine AE, Roger SD: Effects of erythropoietin on blood pressure. Am J Kidney Dis 18:76-83, 1991
59. Vaziri ND: Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 33:821-828, 1999
60. Churchill DN, Muirhead N, Goldstein M, Posen G, Fay W, Beecroft ML, Gorman J, Taylor DW: Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. J Am Soc Nephrol 4:1809-1813, 1994
61. Berns JS, Rudnick MR, Cohen RM, Bower JD, Wood BC: Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. Kidney Int 56:253-260, 1999
62. Conlon PJ, Kovalik E, Schumm D, Minda S, Schwab SJ: Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure. Ren Fail 22:435-444, 2000
63. Movilli E, Pertica N, Camerini C, Cancarini GC, Brunori G, Scolari F, Maiorca R: Predialysis versus postdialysis hematocrit evaluation during erythropoietin therapy. Am J Kidney Dis 39:850-853, 2002
64. Minutolo R, De Nicola L, Bellizzi V, Iodice C, Rubino R, Aucella F, Stallone C, Nappi F, Avella F, Maione E, Conte G, Di Iorio BR: Intra- and posl-dialytic changes of haemoglobin concentrations in non-anaemic haemodialysis patients. Nephrol Dial Transplant 18:2606-2612, 2003
65. Tonelli M, Winkelmayer WC, Jindal KK, Owen WF, Manns BJ: The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int 64:295-304, 2003
66. Macdougall IC, Steering Committee of the CREATE trial, CREATE Study Group: CREATE: new strategies for early anaemia management in renal insufficiency. Nephrol Dial Transplant 18(suppl 2):ii13-ii16, 2003
67. Rao M, Pereira BJ: Prospective trials on anemia of chronic disease: the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). Kidney Int Suppl 87:S12-S19, 2003
68. Strippoli GF, Manno C, Schena FP, Craig JC: Haemoglobin and haematocrit targets for the anaemia of chronic renal disease. Cochrane Database Syst Rev 1:CD003967, 2003